In silico discovery of SARS-CoV-2 main protease inhibitors from the carboline and quinoline database [0.03%]
从卡彬和喹啉数据库中发现冠状病毒主要蛋白酶抑制剂
Eldar Muhtar,Mengyang Wang,Haimei Zhu
Eldar Muhtar
Aim: SARS-CoV-2 caused more than 3.8 million deaths according to the WHO. In this urgent circumstance, we aimed at screening out potential inhibitors targeting the main protease of SARS-CoV-2. Materials & methods: An in-house carboline and ...
Reappraisal of trifluperidol against Nsp3 as a potential therapeutic for novel COVID-19: a molecular docking and dynamics study [0.03%]
针对2019新型冠状病毒Nsp3蛋白的特氟培啶药物再评价：分子对接及动力学研究
Ajita Pandey,Mohit Sharma
Ajita Pandey
Novel COVID-19 is a highly infectious disease that is caused by the recently discovered SARS-CoV-2. It is a fast-spreading disease that urgently requires therapeutics. The current study employed computational regression methods to target th...
Targeting SARS-CoV-2 nonstructural protein 15 endoribonuclease: an in silico perspective [0.03%]
针对SARS-CoV-2非结构蛋白15内切核酸酶的靶向性：一种数字仿真视角
Shafi Mahmud,Abdo A Elfiky,Al Amin et al.
Shafi Mahmud et al.
The newly emerged human coronavirus, SARS-CoV-2, had begun to spread last year and sparked worldwide. In this study, molecular docking is utilized to test some previously approved drugs against the SARS-CoV-2 nonstructural protein 15 (Nsp15...
Chong Chen,Wenhui Zhou,Wenliang Fan et al.
Chong Chen et al.
Aim: COVID-19 is a major threat to public health worldwide. A large proportion of COVID-19 patients is proved to develop anemia. Herein, we investigate the association between anemia and severe pneumonia. Materials & methods: 137 of COVID-1...
Safety, efficacy and acceptability of SARS-CoV-2 vaccines in patients with cancer [0.03%]
癌症患者SARS-CoV-2疫苗的安全性、有效性和可接受度
Roy Chebel,Chris Labaki,Maria Farhat et al.
Roy Chebel et al.
Omar Ashwaq,Pratibha Manickavasagam,Sk Manirul Haque
Omar Ashwaq
One of the many mutations that have occurred in the viral genome is the V483A mutation, which is a part of the receptor-binding motif present in the S1 domain of the spike protein. V483A mutant virus is popular in North America with 36 case...
Archana Tripathy,Nitish Swain,Bhawna Gupta
Archana Tripathy
COVID-19 is a respiratory infection similar to viral pneumonia and is caused by SARS-CoV-2. Chloroquine and hydroxychloroquine make up the major part of the treatment regimen for the management of COVID-19 infections, which are also commonl...
Vertical transmission potential of SARS-CoV-2 from infected mother to twin neonates [0.03%]
SARS-CoV-2感染母亲垂直传播至双胞胎新生儿的潜力
Liangyu Peng,Suliman Khan,Ashaq Ali et al.
Liangyu Peng et al.
Background: Limited details are available regarding the vertical transmission potential of COVID-19 infection in pregnant women. The authors' current study aimed to report the vertical transmission potential of COVID-19 infection in a woman...
Druggability of cavity pockets within SARS-CoV-2 spike glycoprotein and pharmacophore-based drug discovery [0.03%]
针对SARS-CoV-2刺突糖蛋白腔穴的可成药性研究及基于药效团的药物发现方法
Alireza Mohebbi,Fatemeh Sana Askari,Ali Salehnia Sammak et al.
Alireza Mohebbi et al.
Aim: Virus spike glycoprotein of SARS-CoV-2 is a good target for drug discovery. Objective: To examine the potential for druggability of spike protein for pharmacophore-based drug discovery and to investigate the binding affinity of natural...
The Epstein-Barr virus LMP1 interactome: biological implications and therapeutic targets [0.03%]
EB病毒LMP1相互作用组：生物学意义及治疗靶点
Mujeeb R Cheerathodi,David G Meckes Jr
Mujeeb R Cheerathodi
The oncogenic potential of Epstein-Barr virus (EBV) is mostly attributed to latent membrane protein 1 (LMP1), which is essential and sufficient for transformation of fibroblast and primary lymphocytes. LMP1 expression results in the activat...